HIV Drugs available through the BC-CfE

Antiretrovirals and other select medications are available through the BC-CfE’s HIV Treatment Program. These medications may be requested by submitting an HIV Drug Request Prescription Form.

Requests will be assessed according to BC-CfE therapeutic guidelines. Clinical justification and/or supportive documentation may be required. Individuals will obtain, at no cost, medications offered through the BC-CfE’s Drug Treatment Program.

A request for restricted, or non-BC-CfE formulary medications, may be submitted with full documentation supporting the request. These will be subject to clinical review on a case-by-case basis, for consideration of exceptional coverage.

HIV Drugs available through the BC-CfE

The medications listed can be requested by completing and submitting an HIV Drug Treatment Program Prescription Request Form

ART Regimens for Initial Therapy and for Switching ART in Virologically Stable Suppressed Adults

Guideline for Antiretroviral Therapy (ART) Regimens for Initial Therapy and for Switching ART in Virologically Stable Suppressed Adults

HIV Treatment Program Enrolment Form

Completion of this form is required only once for each patient at the time of initial enrolment in the HIV Drug Treatment Program.

HIV Drug Request Prescription Form

For information on how to use this form, and to learn about program eligibility, enrolment, and obtaining HIV medication in BC, please click here.
Cabenuva®

Cabenuva® Recommendations (May 2024)

Cabotegravir and Rilpivirine extended-release injectable suspensions with updated recommendations - May 2024

Cabenuva® Request Form

When requesting Cabenuva® (cabotegravir and rilpivirine) injections, submit this form with the HIV Treatment prescription request form.

Cabenuva® Considerations for the Client

To obtain the greatest benefit from this treatment, and to faciliate the provision of your care, please review this pdf with your clinician, when considering injectable HIV treatment with Cabenuva®
Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below